Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.

被引：0
|
作者：
Raval, Amit D.
Lunacsek, Orsolya
Korn, Matthew J.
Littleton, Natasha
Constantinovici, Niculae
George, Daniel J.
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] Bayer AG, Dexter, MI USA
[3] Bayer Ltd, Dublin, Ireland
[4] Bayer Consumer Care AG, Basel, Switzerland
[5] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17082
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [2] Real-world utilization patterns of radium-223 in metastatic prostate cancer in the United States: An administrative claims database study.
    Raval, Amit D.
    Zhang, Yiqiao
    Korn, Matthew J.
    Constantinovici, Niculae
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 79 - 79
  • [3] Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    BJU INTERNATIONAL, 2025, 135 (03) : 408 - 421
  • [4] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Azad, Arun A.
    Tran, Ben
    Davis, Ian D.
    Parente, Phillip
    Evans, Melanie
    Wong, Shirley
    Brown, Stephen
    Evans, Sue
    Millar, Jeremy
    Murphy, Declan G.
    Papa, Nathan
    INTERNAL MEDICINE JOURNAL, 2022, 52 (08) : 1339 - 1346
  • [6] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
    Horvath, Lisa
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
  • [7] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
    Vaishampayan, U. N.
    Heilbrun, L.
    Monk, P.
    Sonpavde, G.
    Tejwani, S.
    Heath, E. I.
    Fontana, J.
    Chinni, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
    Klier, Jorg
    Koenig, Frank
    Schoenfelder, Robert
    Eichenauer, Rolf
    Johannsen, Manfred
    Beuke, Maike
    Binder, Manfred
    Brenneis, Horst
    Burkert-Scholz, Marcus
    Fieseler, Claus
    Jaeger, Andreas
    Nitz, Christian
    Reese, Stephan
    Romagnolo, Allesandro
    Schroeder, Joerg
    Hempel, Elke
    Doehn, Christian
    AKTUELLE UROLOGIE, 2022, 53 (06) : 517 - 525
  • [9] Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.
    Mondal, Debapriya
    Roy, Somnath
    Bhattacharjee, Arnab
    Roy, Rakesh
    Meyur, Suman
    Biswas, Bivas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
    Rezazadeh, Arash
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kapur, Shivani
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345